Pharmacology of nitrates and other NO donors;PHARMAKOLOGIE DER NITRATE UND ANDERER NO-DONATOREN

Herz

Volumn 21, Issue SUPPL. 1, 1996, Pages 38-49

  Dendorfer, A ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIUM DERIVED RELAXING FACTOR; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; LINSIDOMINE; MOLSIDOMINE; NITRIC ACID DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PENTAERYTHRITYL TETRANITRATE;

DRUG METABOLISM; DRUG TOLERANCE; HUMAN; PHARMACOLOGY; REVIEW;

ANGINA PECTORIS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMODYNAMIC PROCESSES; HUMANS; MUSCLE, SMOOTH, VASCULAR; NITRATES; NITRIC OXIDE; STRUCTURE-ACTIVITY RELATIONSHIP; VASODILATOR AGENTS;

EID: 0029886774     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Abshagen, U., G. Betzien, E. Enderle, B. Kaufmann, G. Neugebauer: Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. Europ. J. clin. Pharmacol. 27 (1985), 637-644.
2. Abshagen, U., S. Spörl-Radun: First data on effects and pharmacokinetics of 1S-5-MN in normal man. Europ. J. clin. Pharmacol. 19 (1981), 423-429.
3. Ahlner, J., R. G. G. Andersson, K. Torfgård, K. L. Axelsson: Organic nitrate esters: Clinical use and mechanisms of actions. Pharmacol. Rev. 43 (1991), 351-423.
4. Armstrong, J. A., S. E. Slaughter, G. S. Marks, P. W. Armstrong: Rapid disappearance of nitroglycerin following incubation with human blood. Canad. J. Physiol. Pharmacol. 58 (1980), 459-462.
5. Bates, J. K. M. T. Baker, R. Guerra Jr., D. G. Harrison: Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem Pharmacol. 42, (Suppl. (1991), S157-S165.
6. Benjamin, N., J. A. E. Dutton, J. M. Ritter: Human vascular smooth muscle cells inhibit platelet aggregation when incubated with glyceryl trinitrate: evidence for generation of nitric oxide. Brit. J. Pharmacol. 102 (1991), 847-850.
7. Bennett, B. M., L. D. Hayward, F. Murad: Effects of the D and L stereoisomers of isosorbide dinitrate on relaxation and cyclic GMP accumulation in rat aorta and comparison to glyceryl trinitrate. J. appl. Cardiol. 1 (1986), 203-209.
8. Bennett, B. M., S. M. Korbus, J. F. Brien, K. Nakatsu, G. S. Marks: Requirement for reduced, unligated hemoprotein for the hemoglobin- and myoglobin-mediated biotransformation of glyceryl trinitrate. J. Pharmacol. exp. Ther. 237 (1986), 629-635.
9. Berkenboom, G., P. Unger, J. Fontaine: Atherosclerosis and responses of human coronary arteries to endothelium-dependent and -independent vasodilators. J. cardiovasc. Pharmacol. 14(Suppl. 11 (1998), S35-S39.
10. Brien, J. F., B. E. McLaughlin, S. M. Kobus, J. H. Kawamoto, K. Nakatsu, G. S. Marks: Mechanism of glyceryl trinitrate-induced vasodilation. I. Relationship between drug biotransformation, tissue cyclic GMP elevation and relaxation of rabbit aorta. J. Pharm. Exp. Ther. 244 (1987), 322-327.
11. Brown, B. G., E. Bolson, R. B. Petersen, C. W. Pierce, H. T. Dodge: The mechanism of nitroglycerin action: vasodilation of stenosis as a major component of the drug response. Circulation 64 (1981), 1089-1097.
12. Davidson, I. W. F., H. S. Miller Jr., F. J. DiCarlo: The pharmacodynamics and biotransformation of pentaerythritol tetranitrate in man. J. Pharmcol. Sci. 60 (1971), 274-277.
13. De Caterina, R., D. Giannessi, F. Crea, S. Chierchia. W. Bernini, P. Gazzetti, A. Abbate: Inhibition of platelet function by injectable isosorbide dinitrate. Amer. J. cardiol. 53 (1984), 1683-1687.
14. Diamond, J., E. B. Chu: Possible role for cyclic GMP in endothelium-dependent relaxation of rabbit aorta by acetylcholine: comparison with nitroglycerin. Res. Commun. chem. Path. Pharmacol. 41 (1983), 369-381.
15. DiCarlo F. J., M. C. Crew, L. S. Brusco, I. W. F. Davidson: Metabolism of pentaerythritol trinitrate. clin. Pharmacol. Ther. 22 (1977), 309-315.
16. Dupois, J., G. Lalonde, R. Remieux, U. Rouleau: Tolerance to intravenous nitrogtycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation, and lack of prevention by N-acetyl cysteine. J. Amer. Coll. Cardiol. 16 (1990), 923-931.
17. Feelisch, M., M. Kelm: Biotransformation of organic nitrates to nitric oxide by cultured vascular smooth muscle and endothelial cells. Biochem. biophys. Res. Commun. 180 (1991), 286-293.
18. Feelisch, M., E. A. Noack: Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Europ. J. Pharmacol. 139 (1987), 19-30.
19. Feelisch, M., J. Ostrowski, E. A. Noack: On the mechanism of NO release from sydnonimines. J Cardiovasc. Pharmacol. 14, Suppl. 11 (1989), S13-S22.
20. Ferrer, M. I., S. E. Bradley, H. O. Wheller, Y Enson, R. Preisig, P. W. Brickner, R. J. Conroy, R. M. Harvey: Some effects of nitroglycerin upon the splanchnic, pulmonary and systemic circulations. Circulation 33 (1966), 357-373.
21. Fuchs, R. M., J. A. Brinker, P. A. Guzman, D. E. Kross, F. C. Yin: Regional coronary blood flow during relief of pacing-induced angina by nitroglycerin. Implications for mechanisms of action. Amer. J. Cardiol. 51 (1983), 19-23.
22. Gerzer, R., C Drummer, B. Karrenbrock, J.-M. Heim: Inhibition of platelet activating factor-induced platelet aggregation by molsidomine, SIN-1, and nitrates in vitro and ex vivo. J. cardiovasc. Pharmacol. Suppl. 11 (1989), S115-S119.
23. Gruetter, C. A., S. M. Lemke: Effects of sulfhydryl reagents on nitroglycerin-induced relaxation of bovine coronary artery. Canad. J. Physiol. Pharmacol. 64 (1986), 1395-1401.
24. Gryglewski, R. J., R. Korbut, E. Trabka-Janik, A. Zembowicz, M. Trybulec: Interaction between NO donors and iloprost in human vascular smooth muscle, platelets, and leukocytes. J. cardiovasc. Pharmacol. 14, Suppl. 11 (1989), S124-S128.
25. Harrison, D. G., J. N. Bates: The nitrovasodilators. New ideas about old drugs. Circulation 87 (1993), 1461-1467.
26. Henry, P. J., J. D. Horowitz, W. J. Louis: Nitroglycerin-induced tolerance affects multiple sites in the organic nitrate bioconversion cascade. J. Pharmacol. exp. Ther. 248 (1989), 762-768.
27. Hodgson, J. R., C C. Lee: Trinitroglycerol metabolism: denitration and glucuronide formation in the rat. Toxicol. appl. Pharmacol. 34 (1975), 449-455.
28. Hogg, N., V. M. Darley-Usmar, M. T. Wilson, S. Moncada: Production of hydroxyl radicals from the simultaneous generation of Superoxide and nitric oxide. Biochem. J. 281 (1992), 419-424.
29. Ivankovich, A. D., D. J. Miletich, J. H. Tinker: Sodium nitroprusside: metabolism and general considerations. Int. Anesth. clin. 16 (1978), 1-29.
30. Kikuchi, K., M. Hirata, A. Nagaoka: Hypotensive action of N-ethoxycarbonyl-3-morpholinosydnonimine, SIN-10. Jap. J. Pharmacol. 20 (1970), 102-115.
31. Kowaluk, E. A., H.-L. Fung: Spontaneous liberation of nitric oxide cannot account for in vitro vascular relaxation by S-nitrosothiols. J. Pharmcol. exp. Ther. 255 (1990), 1256-1264.
32. Kukovetz, W. R., S. Holzmann: Mechanism of vasodilatation by molsidomine. Amer. Heart J. 109 (1985), 637-640.
33. Liu, S., J. S. Beckman, D. D. Ku: Peroxynitirite, a product of Superoxide and nitric oxide, produces coronary vasorelaxation in dogs. J. Pharmcol. exp. Ther. 268 (1994), 1114-1121.
34. Mackenzie, J. E., J. R. Parratt: Comparative effects of glyceryl trinitrate on venous and arterial smooth muscle in vitro; relevance to antianginal activity. Brit. J. Pharmacol. 60 (1977), 155-160
35. Miyazaki, H., I. Masataka, H Yutaka, I. Gen'Ichi, F. Yasuhiko: Simultaneous determination of glyceryl trinitrate and its principal metabolites 1.2- and 1,3-glyceryl dinitrate, in plasma by gas chromatography-negative ion chemical ionization-selected ion monitoring. J. Chromatogr. 239 (1982), 277-286.
36. Moncada, S., R. M. J. Palmer, E. A. Higgs: Nitric oxide: physiology, pathophysiology, and pharmacology, Pharmacol. Rev. 43 (1991), 109-142.
37. Munzel. T., J. Holtz, A. Mülsch, D. J. Stewart, E. Bassenge: Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetyl-cysteine in vivo, but tolerance-independent interactions exist. Circulation 79 (1989), 188-197.
38. Needleman, P., E. M. Johnson: Mechanism of tolerance development to organic nitrates. J. Pharmacol. exp. Ther. 184 (1973), 709-715.
39. Noonan, P. K., L. Z. Benet: The bioavailability of oral nitroglycerin. J. pharm. Sci. 75 (1986), 241-143.
40. Packer, M., W. Hung Lee, P. D. Kessler, S. S. Gottlieb, M. Medina, M. Yushak: Prevention and reversal of nitrate tolerance in patients with congestive heart failure. New Engl. J. Med. 317 (1987), 799-804.
41. Palmer, R. M. J., A. G. Ferrige, S. Moncada: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 (1987), 524-526.
42. Parker, J. C., F. J. DiCarlo, I. W. F. Davidson: Comparative vasodilator effects of nitroglycerin. pentaerythritol trinitrate and biometabolites and other organic nitrates. Europ. J. Pharmacol. 31 (1975), 29-37
43. Parker, J. O., B. Farrell, K. A. Lahey, B. F. Rose: Nitrate tolerance: the lack of effect of N-acetylcysteine. Circulation 76 (1987), 572-576
44. Pohl, U., R. Busse: Endothelium-derived relaxant factor inhibits effects of nitrocompounds in isolated arteries. Am. J. Physiol. 252 (1987), H307-H313.
45. Rudolph, W., J. Dirschinger: Clinical comparison of nitrates and sydnonimines. Furop. Heart J. 12, Suppl. E (1991), 33-41.
46. Schröder, H.: Cytochrome P-450 mediates bioactivation of organic nitrates. J. Pharmcol. exp. Ther. 262 (1992), 298-302.
47. Schröder, H., E. Noack, R. Müller: Evidence for a correlation between nitric oxide formation by cleavage of organic nitrates and activation of guanylate cyclase. J. molec. cell. Cardiol. 17 (1985), 931-934.
48. Servent, D., M. Delaforge, C. Ducrocq, D. Mansuy, M. Lenfant: Nitric oxide formation during microsomal hepatic denitration of glyceryl trinitrate: Involvement of cytochrome P-450. Biochem. biophys. Res. Comm. 163 (1989), 1210-1216.
49. Stamler, J., M. Cunningham, J. Loscalzo: Reduced thiols and the effect of intravenous nitroglycerin on platelet aggregation. Amer. J. Cardiol. 62 (1988), 377-380.
50. Störk, T., M. Möckel, S. Störk, G. Piske, O. Danne, T. Bodemann, R. Müller, H. Eichstädt, H. Hochrein: Hämodynamische Wirkung von Molsidomin bei herzmsuffizienten Koronarkranken mit klinisch manifester Nitrattoleranz. Z. Kardiol. 82 (1993), 293-301.
51. Torresi, J., J. D. Horowitz, G. J. Dunsting: Prevention and reversal of tolerance to nitroglycerine with N-acetylcysteme. J. cardiovasc. Pharmacol. 7 (1985), 777-783.
52. Unger, P., A. Leone, M. Staroukine, S. Degré, G. Berkenboom: Hemodynamic response to molsidomine in patients with ischemic cardiomyopathy tolerant to isosorbide dinitrate. J. cardiovasc. Pharmacol. 18 (1991), 888-894.
53. Vogt, A., H. Kreuzer: Comparative study of the hemodynamic effects of oral molsidomine and isosorbide dinitrate in man. Europ. J. clin. Pharmacol. 23 (1982), 11-14
54. Wagner, F., C. Gohlke-Bärwolf, D. Trenk, E. Jähnchen, H. Roskamm: Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and short-term administration in stable angina pectoris. Europ. Heart J. 12 (1991), 994-999.